| abstract |
The present invention relates to the use of 5α-reductase inhibitors to increase serum HDL cholesterol levels. These compounds may be used together with other lipid lowering agents, such as HMG-CoA reductase inhibitors, squalene synthase inhibitors, HMG-CoA synthase inhibitors, bile acid sequestrants, niacin, probucol, and the fibric acids to reduce the risk of coronary artery disease mortality. Further, two or more 5α-reductase inhibitors may be used in combination to increase serum HDL cholesterol levels. |